Last reviewed · How we verify
QLG1080
QLG1080 is a GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control.
QLG1080 is a GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | QLG1080 |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
QLG1080 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. It also suppresses glucagon release and slows gastric emptying, collectively reducing postprandial and fasting blood glucose levels. This mechanism is typical of the GLP-1 agonist class used in diabetes management.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Hypoglycemia
Key clinical trials
- Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QLG1080 CI brief — competitive landscape report
- QLG1080 updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI